Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ASP Isotopes Inc. (NASDAQ: ASPI) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on ASP Isotopes’ activities as a development stage advanced materials company focused on isotope enrichment technologies, as well as the work of its subsidiaries in nuclear fuels, helium, and related areas.
Through current reports on Form 8-K, ASP Isotopes discloses material events such as the closing of its acquisition of Renergen Limited, a helium and liquefied natural gas producer with operations at the Virginia Gas Project in South Africa. Other 8-K filings describe regulatory approvals for that transaction, private placements of convertible notes issued by its subsidiary Quantum Leap Energy LLC to fund laser enrichment production facilities, and confidential submission of a draft registration statement for a proposed initial public offering of Quantum Leap Energy’s Class A common stock.
The company’s 8-K filings also cover regulatory engagement in the United Kingdom by Quantum Leap Energy Ltd regarding potential High-Assay Low Enriched Uranium (HALEU) production, as well as the acquisition of assets from One 30 Seven Inc. to develop Creber Units for processing water-soluble nuclear waste. These documents provide formal descriptions of transaction terms, use of proceeds, conversion mechanics for notes, and related risk and disclosure language.
ASP Isotopes’ definitive proxy statement on Schedule 14A outlines governance matters, including the annual meeting agenda, director elections, auditor ratification, and voting procedures. The proxy materials also describe the company’s status as an emerging growth company and provide information on its capital structure and shareholder voting rights.
On Stock Titan, investors can use AI-powered tools to read summaries of these filings, quickly identify key sections, and navigate to specific topics such as capital raises, acquisitions, nuclear fuel cycle initiatives, or governance changes. Real-time updates from EDGAR ensure that new 8-Ks, proxy statements, and other relevant filings for ASPI are available as they are published, helping users follow how ASP Isotopes documents its strategic transactions, financing activities, and regulatory developments.
On 23 Jul 2025 ASP Isotopes Inc. (ASPI) executed an Underwriting Agreement with Cantor Fitzgerald covering a registered direct offering of 7,500,000 common shares at $8.00 each. The underwriters will acquire the shares at $7.52, reflecting customary underwriting fees.
ASPI projects net proceeds of ≈ $56.2 million after commissions and expenses. Closing is slated for 25 Jul 2025, subject to standard conditions, under the company’s effective Form S-3 shelf (File No. 333-286860) and a related Rule 462(b) registration statement.
Simultaneously, the company terminated its unused $25 million at-the-market Equity Distribution Agreement with Canaccord Genuity, opting instead for the fully underwritten raise. Exhibits include the underwriting agreement (1.1), Blank Rome LLP legal opinion (5.1), and a pricing press release (99.1).
ASP Isotopes (Nasdaq: ASPI) is raising $60 million through a firmly underwritten public offering of 7.5 million new shares at $8.00, a 20% discount to the $10.00 last close. After $3.6 million in underwriting fees and $0.2 million expenses, net proceeds will be ≈$56.2 million. Outstanding shares will rise 9% to 91.6 million, creating immediate dilution of $6.80 per share; adjusted tangible book value moves from $0.54 to $1.20.
Management plans to deploy cash for general corporate purposes and cap-ex as it transitions from commissioning to initial commercial production of C-14, Si-28 and Yb-176 in 2025. Pro-forma cash (3/31/25 balance $56 million + summer raises + this offering) extends the runway beyond 12 months.
Strategic catalysts include: 1) a $22 million TerraPower loan and two HALEU supply agreements valued up to $4.1 billion over 2027-37 (subject to licensing and plant completion); 2) the proposed all-stock acquisition of Renergen (max 14.27 million ASPI shares) to add helium/LNG assets; 3) a planned H2-25 spin-out of Quantum Leap Energy, its HALEU subsidiary. Each transaction faces regulatory, funding and execution risk.
The company remains pre-revenue, reporting <$8.4 million> Q1-25 net loss and <$32.3 million> FY-24 loss, and warns it may need additional capital. Shares have traded between $0.32 and $10.49 since IPO, highlighting volatility.
ASP Isotopes (ASPI) is raising $60 M gross ($56.4 M net) via a 7.5 M share follow-on priced at $8, a 20% discount to the $10.00 last sale. The new total share count will be about 91.6 M. Proceeds are earmarked for general corporate purposes and extend liquidity beyond 12 months; cash at 3/31/25 was $56 M and the company has since raised an additional $51.7 M.
The company is commercialising isotope-enrichment technologies (ASP & QE) and reports commissioning of three South African plants (C-14, Si-28, Yb-176) with first product expected in 2025. Major strategic actions include: 1) $22 M TerraPower loan plus two HALEU supply agreements valued up to $4.1 B through 2037; 2) planned spin-out of Quantum Leap Energy (HALEU & Li-6) in H2-25; and 3) an all-share acquisition of Renergen (up to 14.27 M ASPI shares) that would add helium/LNG assets, pending multiple regulatory approvals.
ASPI remains pre-revenue, logging net losses of $8.4 M in Q1-25 and $32.3 M in FY-24. The offer dilutes existing holders by an estimated $6.80 per share of tangible book value. Underwriters Cantor and Canaccord will deliver shares on or about 25 Jul 25; lock-ups run 90 days (company) and 75 days (insiders).
On July 11, 2025, ASP Isotopes Inc. (NASDAQ: ASPI) filed a Form 8-K (Item 8.01) to disclose that shareholders of Renergen Limited have approved the scheme of arrangement for ASP Isotopes’ proposed acquisition. The approval eliminates a major condition precedent and materially advances the transaction toward closing. A press release describing the vote is attached as Exhibit 99.1 (the fifth and sixth paragraphs are expressly excluded from incorporation by reference).
The filing contains no purchase price, financing structure, or anticipated closing timetable, and it includes no additional financial statements under Item 9.01 beyond the press-release exhibit. Accordingly, the report functions primarily as a regulatory notice highlighting a positive milestone in ASP Isotopes’ M&A strategy rather than providing quantitative information.